Cortexin vs Cerebrolysin: Differences, Research & How to Choose

Cortexin and Cerebrolysin are both injectable neuropeptide complexes extracted from animal brain tissue and used for neuroprotection, stroke recovery, and cognition. The core difference: Cerebrolysin is a porcine brain-protein blend with the deeper international clinical-trial record (stroke, TBI, Alzheimer’s), while Cortexin is a cortex-derived complex resting mostly on decades of Russian/Eastern European clinical practice.

TL;DR: If your research interest is stroke or traumatic brain injury (TBI) recovery, Cerebrolysin has the more developed evidence base and the broader international trial history, dosed at 5 mL intramuscularly (IM) over 10–30 days. Cortexin is the leaner, fixed-dose option — 10 mg IM daily for 10 days, repeated every 3–6 months — with a long Eastern European track record but far less Western-visible trial data. Both are not FDA-approved in the United States and are handled there as research compounds only; both are prescription pharmaceuticals in Russia/Eastern Europe (and, for Cerebrolysin, additional countries). Neither has a U.S. medical indication.

Research-use & affiliate disclosure: VialBase publishes educational information for research and harm-reduction purposes only. Nothing here is medical advice, a prescription, or an endorsement to use any compound in humans. Neither Cortexin nor Cerebrolysin is approved by the U.S. FDA. VialBase does not sell either compound, recommends no specific vendor, and earns no affiliate commission on this page.

At a Glance

The fastest way to see how the two compare. Every value below is drawn from the VialBase compound profiles; where the source notes do not specify a number, that is stated rather than guessed.

One-line read: same therapeutic territory, different extraction and different depth of evidence. Cerebrolysin is the better-studied, more flexible-dose option; Cortexin is the simpler fixed-course protocol with a longer regional tradition but a thinner published-trial footprint.

What Is Cortexin?

Cortexin is a polypeptide complex isolated from the cerebral cortex of cattle (calf) or pigs that acts as a neurotrophic factor — supporting synaptic plasticity, antioxidant defense, and cerebral blood flow. It is not a single defined peptide like Semax or Selank; it is a mixture of neuropeptides and related fractions extracted from brain tissue, placing it in the same “tissue-derived bioregulator” category as Cerebrolysin. See the full profile at cortexin.

In the regions where it is approved, Cortexin is used in clinical neurorehabilitation to support recovery from cerebrovascular events and to address cognitive impairment. Its proposed activity centers on supporting the brain’s own repair and plasticity machinery rather than acting on a single receptor. Because it is a biological extract, its exact composition can vary by manufacturer, and the source material does not specify a defined molecular weight or amino-acid sequence. Published descriptions characterize it as a lyophilized cortex extract comprising water-soluble neuropeptides, L-amino acids, vitamins, and trace elements, with the manufacturing process said to retain chromatin fragments containing DNA [Ref 13] — i.e., a mixture rather than a single defined peptide. Note that the most detailed mechanistic and compositional account is a Russian-language review (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova), which is indexed in PubMed but not independently corroborated in the broader English-language literature.

What Is Cerebrolysin?

Cerebrolysin is a peptidergic neurotrophic preparation manufactured from pig (porcine) brain proteins, containing a standardized mix of low-molecular-weight peptides and free amino acids that are reported to cross the blood-brain barrier and mimic the brain’s own neurotrophic factors. Full profile: cerebrolysin.

Like Cortexin, it behaves as a complex — its effects are attributed to the combined activity of many small peptides rather than one defined molecule. It has one of the longer histories of clinical use among neuropeptides, applied internationally to neurodegenerative disease, traumatic brain injury, and stroke rehabilitation. A defining feature is that its small peptide fraction is reported to cross the blood-brain barrier, which is the basis for its use as a directly neuroactive (rather than peripheral) agent.

Key Differences

Cortexin and Cerebrolysin look similar on the shelf — both are lyophilized, animal-brain-derived, injectable neuropeptide complexes used for the same broad indications. The differences that matter are in composition, source tissue, mechanism emphasis, and — most importantly — depth of evidence.

1. Composition and source tissue

• Cortexin is extracted specifically from the cerebral cortex of cattle or pigs. It is described as a polypeptide complex.
• Cerebrolysin is made from whole porcine brain proteins and is characterized as a standardized mix of low-molecular-weight peptides plus free amino acids.

Practically: Cerebrolysin’s composition is described as standardized and is explicitly noted to include a blood-brain-barrier-crossing peptide fraction; Cortexin’s source notes do not specify standardization, BBB penetration, or a defined molecular profile. The one indexed, English-language experimental check on Cortexin’s BBB penetration is a 2021 rodent study, which found radiolabeled Cortexin reached mouse brain at concentrations equal to roughly 6–8% of whole-blood levels and bound AMPA, kainate, mGluR1, GABA-A, and mGluR5 receptors in vitro [Ref 10]. That is genuine evidence of BBB crossing and receptor activity, but it is preclinical (animal/in-vitro) and was co-authored by staff of the product’s manufacturer, so it should not be over-read as a human-standardization claim. No comparable independent standardization or human pharmacokinetic data for Cortexin appears in the indexed literature.

2. Mechanism emphasis

Both are multi-target neurotrophic complexes, not single-receptor agonists. But the source material emphasizes slightly different mechanisms for each:

Read this way, Cortexin leans toward perfusion + oxidative-defense + plasticity, while Cerebrolysin leans toward neurogenesis + anti-apoptotic protection + glial calming. Both converge on synaptic plasticity. These are the mechanisms attributed in the source notes. The mechanistic data that does exist is largely preclinical: for Cortexin, in-vitro receptor screening shows binding to glutamatergic (AMPA, kainate, mGluR1, mGluR5) and GABAergic (GABA-A) receptors and antioxidant-system effects in ischemic rats [Ref 10]; for Cerebrolysin, animal work attributes its effects to neurotrophic-factor mimicry, enhanced neurogenesis, and anti-apoptotic signaling [Ref 8]. Receptor-level human pathway data is not established for either compound — the molecular mechanism claims rest on animal and cell models, not on human mechanistic studies.

3. Depth of evidence — the honest comparison

This is the single most important distinction for anyone choosing between them, so it gets stated plainly:

• Cerebrolysin has the deeper, more internationally visible evidence base — but that evidence is genuinely mixed, and the honest reading is more cautious than the marketing. The strongest, most independent appraisal is the 2023 Cochrane systematic review of Cerebrolysin for acute ischaemic stroke (7 RCTs, 1,773 participants), which concluded that Cerebrolysin probably results in little to no difference in all-cause death (risk ratio 0.96, 95% CI 0.65–1.41; moderate-certainty evidence), probably has no beneficial effect on the total number of people with serious adverse events, and may actually increase non-fatal serious adverse events [Ref 4]. In short: the leading independent review found no convincing survival or disability benefit in stroke and flagged a possible harm signal — and noted that the manufacturer had supported three of the multicentre trials. That verdict sits alongside individual positive trials: the CARS trial (Cerebrolysin + rehabilitation after stroke, N≈208) reported superior upper-limb motor recovery at day 90 [Ref 6]; Alzheimer’s RCTs (Panisset 2002; Alvarez 2011, three-dose) and a 2015 meta-analysis reported dose-dependent improvements in cognition and global function in mild-to-moderate AD [Ref 5, Ref 7, Ref 9]; and the CAPTAIN I TBI trial plus the CAPTAIN meta-analysis suggested benefit on multidimensional outcomes after moderate-to-severe TBI, though CAPTAIN I missed its primary endpoint in the intention-to-treat population and reached significance only per-protocol [Ref 11, Ref 12]. Net: Cerebrolysin is the better-studied compound, but the best independent evidence (Cochrane, stroke) is unconvincing and even mildly cautionary, while the supportive trials are frequently industry-sponsored and of variable quality.

• Cortexin rests primarily on decades of real-world clinical use in Russia and Eastern Europe, not on a body of Western randomized controlled trials, and this shows in the literature. A targeted PubMed search returns ~165 Cortexin records, but the human clinical efficacy studies are overwhelmingly Russian-language, published in a single journal — Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (e.g., Refs 13–15) — and not independently replicated in indexed English-language journals. The most rigorous English-language touchpoint is indirect: the 2023 Cochrane stroke review treated Cortexin as a “Cerebrolysin-like agent” and pooled one 272-participant Cortexin RCT into its acute-ischaemic-stroke analysis, which (as above) found no benefit on death [Ref 4]. The only indexed, English-language experimental Cortexin study is preclinical — the 2021 rat/mouse neuroprotection-and-receptor-binding paper [Ref 10]. Bottom line: Cortexin’s human evidence is real but thinly indexed, single-source, predominantly Russian-language, and not independently verified in the Western literature — treat efficacy claims as low-confidence accordingly.

Bottom line on evidence: treat Cerebrolysin as the compound with the larger and more independently verifiable trial record — but one where the single most authoritative independent appraisal (the Cochrane stroke review) is unconvincing and mildly cautionary, and the positive trials are mostly industry-sponsored. Treat Cortexin as the compound with the longer regional clinical tradition but a thin, predominantly Russian-language, largely unreplicated published footprint. Specific-trial assertions in this article are now cited to the primary literature (see ## References); claims that rest only on weak or non-English-indexed sources are flagged in the prose and graded down.

Which Is Better For…

“Better” depends entirely on the research goal. Here is the per-goal read, graded by what the source material actually supports.

Cognitive enhancement

Both are described as supporting memory and cognition, but neither is an approved cognitive-enhancement drug, and the evidence for healthy-user nootropic effect is the weakest part of both profiles.

• Cerebrolysin carries the more detailed cognitive-benefit language in the source — memory formation/consolidation, decision-making, strategic thinking, task-switching, and executive function — and is the one built into VialBase cognitive stacks (e.g., the Executive Function and Brain Blitz stacks with Semax and Dihexa).
• Cortexin is described more narrowly as supporting memory enhancement via synaptic plasticity.

Edge: Cerebrolysin, on breadth of described cognitive benefit and stack integration. Evidence grade for pure cognitive enhancement in healthy users: low / anecdotal for both; the substantive trials are in clinical populations, not enhancement.

Stroke / TBI recovery research

This is where the two genuinely diverge.

• Cerebrolysin is positioned as a primary stroke- and TBI-recovery agent, with trials referenced in both indications and a dedicated TBI dosing course (5 mL IM daily up to 30 days). It is the more established choice for this research question internationally.
• Cortexin is also used for stroke recovery and cognitive rehabilitation, but the supporting evidence in the source is described at the level of clinical-use tradition, not specific trial outcomes.

Edge: Cerebrolysin, clearly — it has the larger human trial history (CARS in stroke [Ref 6]; CAPTAIN I and the CAPTAIN meta-analysis in TBI [Ref 11, Ref 12]) and an explicit TBI protocol, even though the independent Cochrane stroke verdict on the class is unconvincing [Ref 4]. Important caveat: no head-to-head human trial directly compares Cortexin against Cerebrolysin for stroke or TBI outcomes. The only direct comparison is a preclinical rat study, in which both compounds (and, less so, Actovegin) improved neurological recovery in brain-ischemia models [Ref 10]. So “edge: Cerebrolysin” reflects depth and accessibility of evidence, not a demonstrated human superiority over Cortexin.

Neuroprotection

Both are fundamentally neuroprotective complexes, and this is the use case where they overlap most.

• Cortexin’s neuroprotection story emphasizes antioxidant defense and cerebral blood flow — protecting tissue and improving perfusion.
• Cerebrolysin’s emphasizes anti-apoptotic protection, neurogenesis, and reduced glial inflammation — protecting and rebuilding neurons.

Edge: roughly even, mechanism-dependent. If the research framing is oxidative-stress/perfusion-driven injury, Cortexin’s described profile fits; if it is apoptosis/neurodegeneration/neuroinflammation-driven, Cerebrolysin’s fits. Both claims are mechanism-level, not outcome-quantified in the source.

Budget

The VialBase source notes do not specify a price for either compound, so a definitive cost comparison cannot be made from the vault. Neither compound has a stable, citable published price — both trade through pharmacy and research-supplier channels where per-vial cost varies widely by country, brand, and vendor, so any specific figure here would be unverifiable and quickly stale.

What can be said from the protocols: Cortexin’s standard course is fixed and short (10 mg IM daily for 10 days, a few times a year), which is a smaller and more predictable per-course commitment. Cerebrolysin’s courses run longer and can repeat more often (10–30 day courses plus twice-weekly maintenance), which generally implies more material used over time. On protocol footprint alone, Cortexin is the leaner commitment, but actual cost depends on vial pricing that the source does not provide.

Quick-pick summary

Can You Stack Them?

There is no protocol in the VialBase source material that combines Cortexin and Cerebrolysin together, and because they occupy the same mechanistic territory (overlapping neurotrophic/neuroprotective complexes), stacking the two is best viewed as redundant rather than synergistic — you would largely be doubling up on the same class of effect. The source treats them as alternatives, not partners: Cortexin is explicitly described as an alternative to Cerebrolysin in neurorehabilitation protocols. There is no published pharmacokinetic or safety study on co-administering the two complexes — the indexed literature contains no human or animal data on the combination, so a “Cortexin + Cerebrolysin” stack is unsupported by evidence rather than validated.

What the source does show is that each is stacked with complementary, differently-targeted compounds:

• Cortexin is combined with intranasal Semax and Selank (cognitive drive + calm focus), or paired with Dihexa for broader synaptogenesis-focused neuroprotection.
• Cerebrolysin anchors several VialBase stacks: the Executive Function Stack (with Semax + Dihexa), the Concussion & TBI Recovery Stack (with Dihexa + BPC-157), the Nerve Regeneration Stack (with TB-500 + BPC-157), and the CNS Reset Stack (with DSIP + BPC-157).

Practical read: pick one of the two as the neurotrophic backbone, then stack around it with mechanistically distinct compounds (a synthetic nootropic like Semax, a synaptogenic like Dihexa, a regenerative like BPC-157) — rather than running Cortexin and Cerebrolysin simultaneously.

Side Effects & Safety Comparison

Both are described as generally well tolerated with decades of clinical use. The safety profiles are similar, with one meaningful difference driven by route.

Key safety takeaways:

• Cerebrolysin carries the slightly higher safety ceiling, mostly because IV infusion is part of its clinical use — that route introduces allergic/anaphylactic risk (porcine-derived), warrants liver-enzyme and CBC monitoring, and adds an intracranial-pressure headache flag. The source explicitly says to stop an infusion immediately if an allergic reaction occurs.
• Cortexin is monitored more lightly — routine CMP/CBC rather than compound-specific organ surveillance — consistent with its IM-only, fixed-course use and minimal described systemic impact.
• Both are animal-tissue-derived biological extracts, so hypersensitivity is a real consideration for each, and product/composition variability between manufacturers makes sourcing quality important.
• Long-term human safety data beyond established clinical applications is not detailed in the source for either compound, and the independent literature is limited. The best appraisals come from the Cochrane reviews: for Cerebrolysin in stroke, serious adverse events were not reduced and non-fatal serious adverse events may be increased (moderate-certainty evidence) [Ref 4]; in vascular dementia, the pooled adverse-event rate did not differ from placebo but rested on very low-quality evidence (risk ratio 0.91, 95% CI 0.29–2.85) [Ref 2]. There is no comparable long-term safety surveillance dataset for Cortexin in the indexed English-language literature. In other words, “generally well tolerated” is the fair short-term read, but long-term safety for both is under-characterized, and the one quality safety signal that exists (Cerebrolysin SAEs in stroke) is cautionary, not reassuring.

Neither compound is FDA-approved in the U.S., and neither is intended to diagnose, treat, cure, or prevent any disease.

Where to Buy

VialBase does not sell Cortexin or Cerebrolysin, recommends no specific vendor, and earns no affiliate commission on this page. This section is informational only.

Both compounds are research compounds in the United States — neither is FDA-approved, so neither is available as a U.S. prescription product. Internationally, the picture differs slightly:

• Cortexin is widely available through pharmacies in Russia and Eastern Europe, where it is in clinical use, and internationally through research-chemical and international-pharmacy channels. Its injectable origin is Russia / Eastern Europe.
• Cerebrolysin is approved and marketed as a pharmaceutical in several countries (including Russia and parts of Eastern Europe), and is typically obtained internationally through pharmacies or research suppliers. The manufacturer of record is EVER Neuro Pharma GmbH (Austria) [Ref 16], with some production/packaging also done in Russia; its injectable origin therefore spans Austria / Russia. Cortexin’s manufacturer of record is Geropharm (St. Petersburg, Russia) [Ref 16].

Because both are animal-brain-derived biological injectables, provenance and handling matter more than for synthetic single-sequence peptides. If you are sourcing either for research:

• Choose third-party-tested vendors that publish independent certificates of analysis (COAs) confirming identity, purity, and absence of contaminants for the specific lot.
• Prioritize sterility / endotoxin testing and transparent cold-chain handling — these are injectables.
• Avoid any vendor that cannot document what is actually in the vial.
• Always comply with the laws and regulations applicable in your jurisdiction.

Frequently Asked Questions

What is the main difference between Cortexin and Cerebrolysin? Both are injectable animal-brain-derived neuropeptide complexes used for neuroprotection and stroke/TBI recovery. The main difference is evidence depth and composition: Cerebrolysin is a porcine whole-brain blend with a deeper international trial record (stroke, TBI, Alzheimer’s referenced), while Cortexin is a cortex-derived complex resting mainly on decades of Russian/Eastern European clinical practice.

Which is better for stroke or TBI recovery? Cerebrolysin has the stronger position for stroke and TBI research. The source material references clinical trials in both indications and includes a dedicated TBI course (5 mL IM daily for up to 30 days). Cortexin is also used for stroke recovery but is supported mainly by clinical-use tradition rather than specific cited trial outcomes, making Cerebrolysin the better-evidenced choice here.

Are Cortexin and Cerebrolysin FDA-approved? Neither Cortexin nor Cerebrolysin is FDA-approved in the United States; both are handled there as research-use-only compounds with no U.S. medical indication. Both are used clinically as prescription pharmaceuticals in Russia and Eastern Europe, and Cerebrolysin is approved in additional countries internationally. Always follow the laws applicable in your jurisdiction.

How do their doses compare? Cortexin uses a fixed, short course: 10 mg intramuscularly once daily for 10 consecutive days, repeated every 3–6 months. Cerebrolysin uses 5 mL intramuscularly, daily or every other day, for 10–20 days (up to 30 days for TBI), with optional 5 mL twice-weekly maintenance. Cortexin is the leaner protocol; Cerebrolysin is more flexible. This is research-use reference information, not medical advice.

Can you stack Cortexin and Cerebrolysin together? No VialBase protocol combines them, and because they share the same neurotrophic mechanism class, stacking the two is generally redundant rather than synergistic. The source treats them as alternatives. The better approach is to pick one as the backbone and stack it with mechanistically distinct compounds such as Semax, Dihexa, or BPC-157.

Which has more side effects? Both are generally well tolerated, but Cerebrolysin carries a slightly higher safety ceiling because intravenous infusion is part of its clinical use — adding allergic/anaphylactic risk (porcine-derived), liver-enzyme and CBC monitoring, and an intracranial-pressure headache flag. Cortexin, given IM-only in a fixed course, is monitored more lightly with routine CMP/CBC.

Which is cheaper, Cortexin or Cerebrolysin? The VialBase source material does not specify pricing for either compound, so a definitive cost comparison is not possible from the vault. On protocol footprint alone, Cortexin’s fixed 10-day course (a few times per year) is a smaller, more predictable commitment than Cerebrolysin’s longer, more frequently repeated courses, but actual cost depends on vendor vial pricing, which is not standardized or stably published and varies widely by country and supplier.

References

VialBase background sources for both compound profiles, dosing, stacks, and safety notes: The Ultimate Peptides Bible (2026 Edition) by Tom Ralston, the Cortexin and Cerebrolysin compound profiles, and the Cognitive & Nootropic Peptides Bloodwork Guide. The efficacy, mechanism, and safety claims below are cited to the primary peer-reviewed literature (PubMed/DOI), verified against the source records.

Honesty note on the evidence: Cerebrolysin has a substantial international trial record, but it is mixed — the leading independent appraisal (the Cochrane acute-ischaemic-stroke review, Ref 4) found no convincing benefit on death or disability and flagged a possible increase in non-fatal serious adverse events, and most supportive trials are manufacturer-sponsored. Cortexin’s human evidence is predominantly Russian-language, concentrated in a single journal (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova), and not independently replicated in indexed English-language journals (Refs 13–15); its only indexed English-language experimental data are preclinical (Ref 10). Where a claim rests only on such weak or non-English-indexed sources, it is graded down in the prose rather than presented as established. Pricing and direct head-to-head human comparisons are not citable because no reliable published sources exist.

1. Ralston T. The Ultimate Peptides Bible (2026 Edition) — Cortexin profile (composition, dosing, mechanism, safety) and Cerebrolysin profile (composition, dosing, mechanism, stacks, safety).
2. Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11):CD008900. DOI: 10.1002/14651858.CD008900.pub3. PMID: 31710397. (6 RCTs, 597 participants; pooled cognition SMD 0.36, 95% CI 0.13–0.58, very low-quality evidence; adverse-event RR 0.91, 95% CI 0.29–2.85; authors: improvements “not definitive… high risk of bias.”)
3. Cognitive & Nootropic Peptides Bloodwork Guide (VialBase research library) — baseline/on-cycle monitoring and reference ranges.
4. Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026. DOI: 10.1002/14651858.CD007026.pub7. PMID: 37818733. (7 RCTs, 1,773 participants, incl. one 272-participant Cortexin RCT; all-cause death RR 0.96, 95% CI 0.65–1.41, moderate certainty; “probably has no beneficial effect on the total number of people with serious adverse events” and “a potential increase in non-fatal serious adverse events.”)
5. Gauthier S, Proaño JV, Jia J, Froelich L, et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. DOI: 10.1159/000377672. PMID: 25832905.
6. Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-9. DOI: 10.1161/STROKEAHA.115.009416. PMID: 26564102. (Upper-limb motor recovery, ARAT day 90: Mann-Whitney 0.71, 95% CI 0.63–0.79, P<0.0001.)
7. Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, et al. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol. 2011;18(1):59-68. DOI: 10.1111/j.1468-1331.2010.03092.x. PMID: 20500802.
8. Zhang C, Chopp M, Cui Y, Wang L, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. 2010;88(15):3275-81. DOI: 10.1002/jnr.22495. PMID: 20857512. (Preclinical/rat — basis for the neurogenesis mechanism claim.)
9. Panisset M, Gauthier S, Moessler H, Windisch M; Cerebrolysin Study Group. Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm (Vienna). 2002;109(7-8):1089-104. DOI: 10.1007/s007020200092. PMID: 12111446.
10. Kurkin DV, Bakulin DA, Morkovin EI, Kalatanova AV, et al. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One. 2021;16(7):e0254493. DOI: 10.1371/journal.pone.0254493. PMID: 34260655. (Preclinical/animal, partly manufacturer-affiliated: radiolabeled Cortexin crossed into mouse brain at 6–8% of blood levels; in-vitro binding to AMPA, kainate, mGluR1, GABA-A, mGluR5 receptors.)
11. Poon W, Matula C, Vos PE, Muresanu DF, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41(2):281-93. DOI: 10.1007/s10072-019-04053-5. PMID: 31494820. (N=46; primary multivariate endpoint not significant in ITT, significant per-protocol.)
12. Vester JC, Buzoianu AD, Florian SI, Hömberg V, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(11):4531-41. DOI: 10.1007/s10072-020-04974-6. PMID: 33620612.
13. Gomazkov OA. [Cortexin. Molecular mechanisms and targets of neuroprotective activity]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(8):99-104. DOI: 10.17116/jnevro20151158199-104. PMID: 26356623. (Russian-language review — basis for the Cortexin composition description; not independently corroborated in English-language literature.)
14. Belova LA, Mashin VV, Abramova VV, Proshin AN, et al. [Efficacy of cortexin in acute and recovery periods of hemispheric ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10):38-42. DOI: 10.17116/jnevro201611610138-42. PMID: 27845314. (Russian-language.)
15. Khabirov FA, Khaibullin TI, Granatov EV, Akhmetova GI, et al. [Comparison of the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(12 Pt 2):11-15. DOI: 10.17116/jnevro202012012211. PMID: 33449527. (Russian-language; representative of the single-source Cortexin clinical literature — see also Aliferova et al., 2014, PMID 24874316.)
16. Manufacturer of record: Cerebrolysin — EVER Neuro Pharma GmbH (Austria) (https://www.everpharma.com/products/cerebrolysin/); Cortexin — Geropharm (St. Petersburg, Russia). Country-of-origin / manufacturer attribution, not a clinical-evidence source.

Disclosure: This article is for educational and research-use purposes only and is not medical advice. VialBase does not sell Cortexin or Cerebrolysin and has no affiliate relationship associated with this page. Consult a qualified healthcare professional before making any health decision.

JSON-LD (for <head>)

{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "MedicalWebPage",
      "@id": "https://vialbase.com/compare/cortexin-vs-cerebrolysin#webpage",
      "url": "https://vialbase.com/compare/cortexin-vs-cerebrolysin",
      "name": "Cortexin vs Cerebrolysin: Differences, Research & How to Choose",
      "headline": "Cortexin vs Cerebrolysin: Differences, Research & How to Choose",
      "description": "Cortexin vs Cerebrolysin compared on composition, evidence depth, dosing, safety, and which fits each research goal. Both are research compounds in the US; neither is FDA-approved.",
      "inLanguage": "en",
      "lastReviewed": "2026-06-05",
      "isPartOf": {
        "@type": "WebSite",
        "name": "VialBase",
        "url": "https://vialbase.com"
      },
      "publisher": {
        "@type": "Organization",
        "name": "VialBase",
        "url": "https://vialbase.com"
      },
      "about": [
        {
          "@type": "MedicalEntity",
          "name": "Cortexin",
          "alternateName": "Cortexin polypeptide cortex complex",
          "description": "A polypeptide complex extracted from bovine or porcine cerebral cortex that acts as a neurotrophic factor, supporting synaptic plasticity, antioxidant defense, and cerebral blood flow. Not FDA-approved; research use only in the United States."
        },
        {
          "@type": "MedicalEntity",
          "name": "Cerebrolysin",
          "alternateName": "Porcine brain-derived neuropeptide complex",
          "description": "A peptidergic neurotrophic preparation derived from pig brain proteins, containing low-molecular-weight peptides and free amino acids reported to cross the blood-brain barrier. Used internationally for stroke, TBI, and neurodegenerative conditions. Not FDA-approved in the United States."
        }
      ],
      "mainEntity": {
        "@type": "MedicalGuideline",
        "name": "Cortexin vs Cerebrolysin research-use comparison reference",
        "evidenceLevel": "https://schema.org/EvidenceLevelC",
        "guidelineSubject": [
          { "@type": "MedicalEntity", "name": "Cortexin" },
          { "@type": "MedicalEntity", "name": "Cerebrolysin" }
        ]
      },
      "mainContentOfPage": {
        "@type": "WebPageElement",
        "speakable": {
          "@type": "SpeakableSpecification",
          "cssSelector": ["h1", "p"]
        }
      }
    },
    {
      "@type": "FAQPage",
      "@id": "https://vialbase.com/compare/cortexin-vs-cerebrolysin#faq",
      "mainEntity": [
        {
          "@type": "Question",
          "name": "What is the main difference between Cortexin and Cerebrolysin?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Both are injectable animal-brain-derived neuropeptide complexes used for neuroprotection and stroke/TBI recovery. The main difference is evidence depth and composition: Cerebrolysin is a porcine whole-brain blend with a deeper international trial record (stroke, TBI, Alzheimer's referenced), while Cortexin is a cortex-derived complex resting mainly on decades of Russian and Eastern European clinical practice."
          }
        },
        {
          "@type": "Question",
          "name": "Which is better for stroke or TBI recovery?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Cerebrolysin has the stronger position for stroke and TBI research. The source material references clinical trials in both indications and includes a dedicated TBI course of 5 mL IM daily for up to 30 days. Cortexin is also used for stroke recovery but is supported mainly by clinical-use tradition rather than specific cited trial outcomes, making Cerebrolysin the better-evidenced choice."
          }
        },
        {
          "@type": "Question",
          "name": "Are Cortexin and Cerebrolysin FDA-approved?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Neither Cortexin nor Cerebrolysin is FDA-approved in the United States; both are handled there as research-use-only compounds with no US medical indication. Both are used clinically as prescription pharmaceuticals in Russia and Eastern Europe, and Cerebrolysin is approved in additional countries internationally. Always follow the laws applicable in your jurisdiction."
          }
        },
        {
          "@type": "Question",
          "name": "How do the doses of Cortexin and Cerebrolysin compare?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Cortexin uses a fixed, short course: 10 mg intramuscularly once daily for 10 consecutive days, repeated every 3 to 6 months. Cerebrolysin uses 5 mL intramuscularly, daily or every other day, for 10 to 20 days (up to 30 for TBI), with optional 5 mL twice-weekly maintenance. Cortexin is the leaner protocol; Cerebrolysin is more flexible. This is research-use reference information, not medical advice."
          }
        },
        {
          "@type": "Question",
          "name": "Can you stack Cortexin and Cerebrolysin together?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "No VialBase protocol combines them, and because they share the same neurotrophic mechanism class, stacking the two is generally redundant rather than synergistic. The source treats them as alternatives. The better approach is to pick one as the backbone and stack it with mechanistically distinct compounds such as Semax, Dihexa, or BPC-157."
          }
        },
        {
          "@type": "Question",
          "name": "Which has more side effects, Cortexin or Cerebrolysin?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "Both are generally well tolerated, but Cerebrolysin carries a slightly higher safety ceiling because intravenous infusion is part of its clinical use, adding allergic and anaphylactic risk (porcine-derived), liver-enzyme and CBC monitoring, and an intracranial-pressure headache flag. Cortexin, given intramuscularly in a fixed course, is monitored more lightly with routine CMP and CBC."
          }
        },
        {
          "@type": "Question",
          "name": "Which is cheaper, Cortexin or Cerebrolysin?",
          "acceptedAnswer": {
            "@type": "Answer",
            "text": "The VialBase source material does not specify pricing for either compound, so a definitive cost comparison is not possible from the vault. On protocol footprint alone, Cortexin's fixed 10-day course a few times per year is a smaller, more predictable commitment than Cerebrolysin's longer, more frequently repeated courses, but actual cost depends on vendor vial pricing."
          }
        }
      ]
    },
    {
      "@type": "BreadcrumbList",
      "@id": "https://vialbase.com/compare/cortexin-vs-cerebrolysin#breadcrumb",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://vialbase.com/"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Compare",
          "item": "https://vialbase.com/compare"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Cortexin vs Cerebrolysin",
          "item": "https://vialbase.com/compare/cortexin-vs-cerebrolysin"
        }
      ]
    }
  ]
}